TIDMAPH

Alliance Pharma PLC

03 March 2016

Hardman & Co issues research report on Alliance Pharma

Acquisition impact and future growth opportunity: Alliance Pharma has developed through a series of 28 acquisitions as part of a buy and build strategy, culminating in the most recent GBP127.5m acquisition of 27 primarily dermatology and woundcare products and assets from Sinclair IS Pharma. Not only is this acquisition doubling the size of the company and enhancing EPS by 14%, it should provide the foundations of a more internationally oriented business that can more easily exploit the growth opportunities of its existing products (eg. Hydromol, MacuShield, Diclectin) as well as presenting itself as a credible partner for attracting in-licensing/M&A opportunities.

Please click here for the full report:

http://www.hardmanandco.com/docs/default-source/company-docs/alliance-pharma-documents/alliance-pharma-_-sinclair-acquisition

 
 To contact us:      Contact: Dr Martin Hall 
  Hardman & Co        mh@hardmanandco.com 
  11/12 Tokenhouse    Telephone: +44 20 7929 3399 
  Yard                Follow us on Twitter @HardmanandCo 
  London 
  EC2R 7AS

www.hardmanandco.com

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAGMGGFGZDGVZZ

(END) Dow Jones Newswires

March 03, 2016 02:03 ET (07:03 GMT)

Alliance Pharma (LSE:APH)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more Alliance Pharma Charts.
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more Alliance Pharma Charts.